News

For Tom Foti, Vice President of Scientific Partnerships at Aldevron, the case with baby KJ at the Children’s Hospital of Philadelphia (CHOP) revealed that rapid genomic medicine relies on relationships and infrastructure established long before a patient reaches crisis.

For people with advanced melanoma skin cancer, a treatment utilizing immune cells derived from their own tumours holds great promise. Özcan Met, Associate Professor at Denmark’s National Center for Cancer Immune Therapy (CCIT–DK), is utilizing CRISPR–based gene editing to further improve this personalized, cell-based approach. His work highlights both what it takes to conduct complex clinical trials in an academic setting and why sustaining innovation beyond pilot studies remains challenging.

Personalized gene-editing treatments remain out of reach for most patients in Europe today. To understand why, it helps to look at the front lines. At the Amsterdam UMC ‘CRISPR Clinic’ – one of Europe’s first academic centres dedicated to guiding patients and families on gene-editing options – the systemic gaps become immediately visible.